U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H9N2O3S.Na.H2O
Molecular Weight 254.239
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFACETAMIDE SODIUM

SMILES

O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1

InChI

InChIKey=IHCDKJZZFOUARO-UHFFFAOYSA-M
InChI=1S/C8H10N2O3S.Na.H2O/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;;/h2-5H,9H2,1H3,(H,10,11);;1H2/q;+1;/p-1

HIDE SMILES / InChI

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H10N2O3S
Molecular Weight 214.242
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BLEPHAMIDE

Approved Use

Blephamide ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

Launch Date

-2.61619204E11
Curative
KLARON

Approved Use

Klaron Lotion is indicated in the topical treatment of acne vulgaris.

Launch Date

8.5129921E11
PubMed

PubMed

TitleDatePubMed
Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase.
1990 Feb
Acute infectious conjunctivitis in childhood.
2001 Jul
Spectrophotometric determination of sulphacetamide.
2002 Jul-Aug
Studies on the influence of auxiliary substances on the physico-chemical characteristics of ophthalmic drugs. Part I. Studies on the influence of auxiliary substances on the critical micellar concentration of surfactants solutions in eye drops containing sulphacetamidum natricum.
2002 Jul-Aug
A status report on the medical management of rosacea: focus on topical therapies.
2002 Nov
3-Aminophenol as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives.
2003 Dec
Trends in ophthalmic antimicrobial utilization pattern in Bahrain between 1993 and 2000: a resurgence of chloramphenicol?
2003 Jan
Determination of prednisolone and the most important associated compounds in ocular and cutaneous pharmaceutical preparations by micellar electrokinetic capillary chromatography.
2003 Jan 25
New drugs and dosage forms.
2003 Mar 1
Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection.
2004 Aug 20
Medical treatment of rosacea with emphasis on topical therapies.
2004 Jan
Facial hygiene and comprehensive management of rosacea.
2004 Mar
Investigation of radiosterilization and dosimetric features of sulfacetamide sodium.
2004 Nov 19
Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum.
2004 Sep
Diagnosing and managing the patient with rosacea.
2005 Apr
Broad-specificity immunoassays for sulfonamide detection: immunochemical strategy for generic antibodies and competitors.
2006 Mar 1
Pilot investigation of the hydrating effects of topical acne medications.
2007 Aug
Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.
2007 Mar
[Simultaneous determination of seven sulfonamides and metronidazole and chloramphenicol in cosmetics by high performance liquid chromatography].
2007 Sep
A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical preparations.
2007 Sep
Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea.
2008
Optimal conditions for determination of zinc bacitracin, polymyxin B, oxytetracycline and sulfacetamide in animal feed by micellar electrokinetic capillary chromatography.
2008 Apr
N-(2,6-Dimethyl-phen-yl)-2-methyl-acetamide.
2008 Jan 9
Application of liquid-liquid-liquid microextraction and high-performance liquid-chromatography for the determination of sulfonamides in water.
2008 Mar 31
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
2010
Synthesis and biological activities of some novel triazoloquinazolines and triazinoquinazolines containing benzenesulfonamide moieties.
2010
An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.
2010 Dec
The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses.
2010 Mar
Pharmacokinetic study on the mechanism of interaction of sulfacetamide sodium with bovine serum albumin: a spectroscopic method.
2010 Mar
Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
2010 Nov
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

Topical: apply a thin film to affected areas twice daily. Ophtalmic suspension/ointment: two drops of suspension should be instilled into the conjunctival sac every four hours during the day and at bedtime. A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.
Route of Administration: Other
In Vitro Use Guide
P. aeruginosa, S. marcescens, St. epidermidis, C. albicans, and A. fumigatus (spores) were exposed to two ophthalmic solutions each formulated with 10% sodium sulfacetamide and a preservative. Sulfacetamide solutions preserved with thimerosal have MIC values ranging from 0.2 to 2.8 for the five test microorganisms. The solutions preserved with parabens exhibit slightly higher MIC values for Pseudomonas, Serratia, and spores of Aspergillus (1.5-6.5) and significantly higher MIC values for Staphylococcus and Candida (19.6 and 5.0, respectively).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:07:52 UTC 2023
Edited
by admin
on Fri Dec 15 15:07:52 UTC 2023
Record UNII
4NRT660KJQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFACETAMIDE SODIUM
EP   II   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-IP  
Common Name English
SODIUM SULFACETAMIDE
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF PREDSULFAIR
Common Name English
PREDSULFAIR COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM [ORANGE BOOK]
Common Name English
SULFACETAMIDE SODIUM [WHO-IP]
Common Name English
PREDAMIDE COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM [USP MONOGRAPH]
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF BLEPHAMIDE S.O.P.
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF SULPHRIN
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF SULSTER
Common Name English
SULFACETAMIDE SODIUM [VANDF]
Common Name English
BLEPHAMIDE COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM [EP IMPURITY]
Common Name English
SULFACETAMIDE SODIUM [EP MONOGRAPH]
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF BLEPHAMIDE
Common Name English
SULSTER COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACEL
Brand Name English
SULPHRIN COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF PREDAMIDE
Common Name English
SODIUM N-SULFANILYLACETAMIDE MONOHYDRATE
Systematic Name English
NSC-625324
Code English
FML-S COMPONENT SULFACETAMIDE SODIUM
Common Name English
SODIUM SULAMYD
Brand Name English
SULFACETAMIDE SODIUM COMPONENT OF METIMYD
Common Name English
SULFACETAMIDE SODIUM SALT MONOHYDRATE [MI]
Common Name English
METIMYD COMPONENT SULFACETAMIDE SODIUM
Common Name English
ACETAMIDE, N-((4-AMINOPHENYL)SULFONYL)-, MONOSODIUM SALT, MONOHYDRATE
Common Name English
SULFACETAMIDE SODIUM [MART.]
Common Name English
OCUSULF
Brand Name English
BLEPH
Brand Name English
CETAPRED COMPONENT SULFACETAMIDE SODIUM
Common Name English
KLARON
Brand Name English
SULFACETAMIDE SODIUM COMPONENT OF ISOPTO CETAPRED
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF FML-S
Common Name English
SULFACETAMIDE SODIUM [USP-RS]
Common Name English
SULFACETAMIDUM NATRICUM [WHO-IP LATIN]
Common Name English
FLAMMAZINE
Common Name English
BLEPHAMIDE S.O.P. COMPONENT SULFACETAMIDE SODIUM
Common Name English
N-Sulfanilylacetamide monosodium salt monohydrate
Common Name English
SULFACETAMIDE SODIUM [II]
Common Name English
ISOPTO CETAPRED COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM COMPONENT OF CETAPRED
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
Code System Code Type Description
CAS
6209-17-2
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
EVMPD
SUB04620MIG
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
PUBCHEM
6419954
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
EPA CompTox
DTXSID50211129
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
FDA UNII
4NRT660KJQ
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
SMS_ID
100000085048
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
ChEMBL
CHEMBL455
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SULFACETAMIDE SODIUM
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY Description: A white or yellowish white, crystalline powder; odourless. Solubility: Soluble in 1.5 parts of water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antiinfective agent. Storage: Sulfacetamide sodium should be kept in a well-closed container, protected from light. Additional information: Even in the absence of light, Sulfacetamide sodium is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Sulfacetamide sodium contains not less than 99.0% and not more than 101.0% of C8H9N2NaO3S, calculated with reference to the anhydrous substance.
MERCK INDEX
m10301
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
RS_ITEM_NUM
1624006
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
NSC
625324
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
CHEBI
9327
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
DAILYMED
4NRT660KJQ
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
RXCUI
82101
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY RxNorm
DRUG BANK
DBSALT000986
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
CHEBI
63858
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
NCI_THESAURUS
C29467
Created by admin on Fri Dec 15 15:07:52 UTC 2023 , Edited by admin on Fri Dec 15 15:07:52 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factor: for the calculation of the content, multiply the peak area of impurity A by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY